Supplementary data



Figure S1. Higher levels of LYVE-1 in chondrosarcoma patients. IHC staining was performed for LYVE-1 levels in chondrosarcoma patients, followed by photography and quantification. * $p < 0.05$ versus normal cartilage.



Figure S2. Higher levels of visfatin in chondrosarcoma patients. IHC staining was performed for visfatin levels in chondrosarcoma patients, followed by photography and quantification. * $p < 0.05$ versus normal cartilage.



Figure S3. Visfatin increases VEGF-C expression in chondrosarcoma. JJ012 cells were treated with visfatin, the VEGF-C mRNA expression was examined by qPCR.



Figure S4. The pharmacological inhibitors did not affect basal levels of VEGF-D. JJ012 cells were treated with indicated inhibitors, the VEGF-D mRNA expression was examined by qPCR.



Figure S5. Higher levels of VEGF-D in osteosarcoma patients. IHC staining was performed for VEGF-D levels in osteosarcoma patients, followed by photography.